ATE370416T1 - Neurosteroide als marker für die alzheimersche krankheit - Google Patents
Neurosteroide als marker für die alzheimersche krankheitInfo
- Publication number
- ATE370416T1 ATE370416T1 AT01903310T AT01903310T ATE370416T1 AT E370416 T1 ATE370416 T1 AT E370416T1 AT 01903310 T AT01903310 T AT 01903310T AT 01903310 T AT01903310 T AT 01903310T AT E370416 T1 ATE370416 T1 AT E370416T1
- Authority
- AT
- Austria
- Prior art keywords
- neurosteroids
- disease
- alzheimer
- markers
- onset
- Prior art date
Links
- 239000002858 neurotransmitter agent Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007171 neuropathology Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17869800P | 2000-01-28 | 2000-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370416T1 true ATE370416T1 (de) | 2007-09-15 |
Family
ID=22653575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01903310T ATE370416T1 (de) | 2000-01-28 | 2001-01-26 | Neurosteroide als marker für die alzheimersche krankheit |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1254251B1 (https=) |
| JP (1) | JP2004507712A (https=) |
| AT (1) | ATE370416T1 (https=) |
| AU (2) | AU785364B2 (https=) |
| CA (1) | CA2398358A1 (https=) |
| DE (1) | DE60129932T2 (https=) |
| ES (1) | ES2290111T3 (https=) |
| WO (1) | WO2001055692A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003100092A2 (en) * | 2002-05-28 | 2003-12-04 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases |
| FR2847038B1 (fr) * | 2002-11-07 | 2005-01-07 | Conservatoire Nat Arts | Procede de diagnostic de maladies neurodegeneratives |
| US7576073B2 (en) | 2004-05-28 | 2009-08-18 | UNIVERSITé LAVAL | Combined therapy for the treatment of parkinson's disease |
| CN102998464A (zh) * | 2011-09-16 | 2013-03-27 | 武汉优尔生科技股份有限公司 | 脱氢表雄酮酶联免疫吸附测定试剂盒的研制方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162198A (en) * | 1991-02-08 | 1992-11-10 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation |
| US6146836A (en) * | 1997-05-19 | 2000-11-14 | Bayer Corporation | Immunoassays using anti-allotypic monoclonal antibodies |
-
2001
- 2001-01-26 CA CA002398358A patent/CA2398358A1/en not_active Abandoned
- 2001-01-26 EP EP01903310A patent/EP1254251B1/en not_active Expired - Lifetime
- 2001-01-26 DE DE60129932T patent/DE60129932T2/de not_active Expired - Fee Related
- 2001-01-26 ES ES01903310T patent/ES2290111T3/es not_active Expired - Lifetime
- 2001-01-26 JP JP2001555784A patent/JP2004507712A/ja active Pending
- 2001-01-26 AU AU31142/01A patent/AU785364B2/en not_active Ceased
- 2001-01-26 WO PCT/US2001/002476 patent/WO2001055692A2/en not_active Ceased
- 2001-01-26 AT AT01903310T patent/ATE370416T1/de not_active IP Right Cessation
-
2007
- 2007-04-30 AU AU2007201915A patent/AU2007201915A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001055692A2 (en) | 2001-08-02 |
| AU2007201915A1 (en) | 2007-05-24 |
| CA2398358A1 (en) | 2001-08-02 |
| EP1254251A4 (en) | 2004-07-21 |
| AU3114201A (en) | 2001-08-07 |
| AU785364B2 (en) | 2007-02-01 |
| DE60129932D1 (de) | 2007-09-27 |
| ES2290111T3 (es) | 2008-02-16 |
| DE60129932T2 (de) | 2008-06-19 |
| JP2004507712A (ja) | 2004-03-11 |
| EP1254251A2 (en) | 2002-11-06 |
| EP1254251B1 (en) | 2007-08-15 |
| WO2001055692A3 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004065576A3 (en) | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides | |
| EP1578923A4 (en) | SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES | |
| BRPI0411295A (pt) | compostos e seu uso na terapia | |
| BR0112000A (pt) | Amina, composto, álcool, epóxido, cetona, azida, composição, uso de uma amina, métodos de tratamento de um paciente, de inibição da atividade da beta-secretase, de clivagem da proteìna precursora de amilóide e da produção de peptìdeo amilóide e de placa beta-amilóide em um animal, de tratamento ou prevenção de uma doença distinguida por depósitos de beta-amilóide no cérebro e de produção de um complexo de beta-secretase, e, kit | |
| ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| WO2003065006A3 (en) | Methods and compositions for treating cancer | |
| EP1895017A3 (en) | Use of A33 antigens and JAM-IT | |
| SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| TW200501978A (en) | Use of FGF-18 in the diagnosis and treatment of memory disorders | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
| ATE370416T1 (de) | Neurosteroide als marker für die alzheimersche krankheit | |
| WO2004107958A3 (en) | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
| WO2007059064A3 (en) | Fgf2-related methods for diagnosing and treating depression | |
| CY1110788T1 (el) | Διαγονιδιακα ζωα τα οποια παρουσιαζουν σημαντικες διαταραχες σχετικες με την νοσο alzheimer | |
| GT200000089A (es) | Procedimiento para obtencion de "derivados de etanesulfonil". | |
| WO2003073983A3 (en) | Methods and compositions in treating pain using diacylglycerol kinase epsilon | |
| ATE495269T1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
| FR2856595B1 (fr) | Methodes et compositions pour le traitement de deficits cognitifs. | |
| WO2008070284A3 (en) | Amyloid beta peptides and methods of uses thereof | |
| GB2431348B (en) | Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders | |
| FR2828212B1 (fr) | Methodes de diagnostic et de pronostic de la maladie de parkinson | |
| EP4528274A3 (en) | Biomarkers for neuropathological conditions and methods for diagnosis and monitoring the efficacy of treatment | |
| WO2003061573A3 (en) | Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo | |
| WO2004071411A3 (en) | Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1254251 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |